Rabeximod: a first‑in‑class PGK1 inhibitor aimed at slowing the progression of chronic kidney disease
Our mission
Renity Pharma is committed to transforming care in inflammatory and fibrotic kidney diseases by developing safe, kidney‑targeted therapies that address the critical unmet needs in chronic kidney disease
Rabeximod is a highly selective PGK1 inhibitor, pioneering a novel therapeutic approach in immuno-metabolic regulation.
Uniquely designed to modulate fibrosis‑driving inflammatory pathways.
Innovation Overview
Good safety and efficacy profile in more than 200 patients treated in inflammatory disease indication.
Advancing into renal indications based on robust new non‑clinical evidence supporting PGK1 inhibition as a promising strategy for chronic kidney disease.